🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

15 results for “Centessa” Clear

  1. Lixivaptan

    Centessa Pharmaceuticals plc

    Polycystic Kidney Disease, Adult

    phase 3 small molecule terminated

    2 trials

  2. Lixivaptan

    Centessa Pharmaceuticals plc

    Autosomal Dominant Polycystic Kidney

    phase 3 small molecule terminated

    1 trial

  3. SerpinPC

    Centessa Pharmaceuticals plc

    Hemophilia a

    phase 3 small molecule completed

    3 trials

  4. cleminorexton

    Centessa Pharmaceuticals plc

    Narcolepsy Type 1

    phase 3 small molecule active

    1 trial

  5. A Phase 1/2a, First in Human, Open-Label, Multicenter, Dose Escalation Study with Expansion Cohorts to Evaluate the Safety, Tolerability, and Preliminary Activity of LB101 in Subjects with Advanced Solid Tumors

    Centessa Pharmaceuticals plc

    Advanced solid tumors

    phase 2 other active

    1 trial

  6. Imgatuzumab

    Centessa Pharmaceuticals plc

    Cutaneous Squamous Cell Carcinoma

    phase 2 small molecule terminated

    1 trial

  7. LB101

    Centessa Pharmaceuticals plc

    Advanced Solid Tumor

    phase 2 small molecule terminated

    1 trial

  8. ORX750

    Centessa Pharmaceuticals plc

    Narcolepsy Type 1

    phase 2 small molecule active

    2 trials

  9. ORX750, ORX750, ORX750, ORX750

    Centessa Pharmaceuticals plc

    Narcolepsy and Idiopathic Hypersomnia

    phase 2 small molecule active

    1 trial

  10. ORX750, ORX750, ORX750, Orx750 matching placebo, ORX750

    Centessa Pharmaceuticals plc

    Narcolepsy and Idiopathic Hypersomnia

    phase 2 small molecule active

    1 trial

  11. SerpinPC

    Centessa Pharmaceuticals plc

    Hemophilia B with Inhibitor

    phase 2 small molecule terminated

    1 trial

  12. CBS001

    Centessa Pharmaceuticals plc

    Chronic Inflammatory Disease

    phase 1 small molecule terminated

    1 trial

  13. ORX142 Tablets

    Centessa Pharmaceuticals plc

    Excessive Daytime Sleepiness

    phase 1 small molecule active

    1 trial

  14. ORX489 Tablets

    Centessa Pharmaceuticals plc

    Healthy Adult Male and Female Volunteers

    phase 1 small molecule active

    1 trial

  15. ZF874

    Centessa Pharmaceuticals plc

    Alpha1 Anti-Trypsin Deficiency

    phase 1 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources